Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04764383

Histaminergic Basis of Fatigue in Multiple Sclerosis

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Miami · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The purpose of this research study is to identify a way to improve the feeling of exhaustion that patients might experience because of Multiple Sclerosis (MS).

Conditions

Interventions

TypeNameDescription
DRUGL-Histidine1000 mg capsules taken by mouth (PO) twice daily (BID).
DRUGPlaceboMicrocrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
DRUGLodosyn50 mg capsules taken PO BID.

Timeline

Start date
2022-01-01
Primary completion
2022-10-30
Completion
2022-10-30
First posted
2021-02-21
Last updated
2021-07-29

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04764383. Inclusion in this directory is not an endorsement.